Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer

Chin Clin Oncol. 2024 Apr;13(2):30. doi: 10.21037/cco-23-108. Epub 2024 Apr 3.

Authors

Nicole Conci¹, Andrea De Giglio¹, Francesca Sperandi², Barbara Melotti², Francesco Gelsomino²

Affiliations

¹ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
² Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

PMID: 38600809
DOI: 10.21037/cco-23-108

No abstract available

Keywords: Osimertinib; adjuvant therapy; epidermal growth factor receptor mutation (EGFR mutation); non-small cell lung cancer (NSCLC).

Publication types

Editorial

MeSH terms

Carcinoma, Non-Small-Cell Lung* / genetics
ErbB Receptors* / genetics
Humans
Lung Neoplasms* / genetics
Mutation*

Substances

ErbB Receptors
EGFR protein, human